Bannerbild German Brest Group

GBG-Research at EMSO 2022

03.08.2022

ESMO Congress Paris 2022

We are proud to present our research at ESMO Congress in Paris, September 9th to 13th.2022.

GeparPippa TIP (S. Loibl)

A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)

200TiP poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022

Machine Learning (M. Hägele)

Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies

68MO mini oral Mini Oral session: Basic science & translational research
Location: 7.1.D - Dijon Auditorium, Paris Expo Porte de Versailles, Paris, France
Date: Sun, 11.09.2022 Time: 14:45 - 16:15

BCP biomarker matched (K. Galas)

Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts

151P poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022

Genevieve FU (J. Huober)

Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

168P poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022

BMBC-HER2+ long-term survivor (E. Laakmann)

Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC Registry

269P poster Presentation Topic: Breast cancer, metastatic; Date: Sat, 10.09.2022


Visit the congress website for more information.

News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd